Many inhibitors developed against psoriatic cytokines have shown promising results; for example, secukinumab and ixekizumab targeting IL-17A and brodalumab targeting the IL-17A receptor have been approved by the Food and Drug Administration for treating moderate-to-severe psoriasis (Ferrara et al., 2024; Galluzzo et al., 2016; Hawkes et al., 2018). The gene discussed is IL17A; the disease is psoriasis.